Aga Khan University to develop new, targeted therapies for blood cancer

​AKU’s Centre for Regenerative Medicine and Stem Cell Research (CRM) is to develop new, targeted therapies for a common form of blood cancer in adults, Philadelphia chromosome positive (Ph+) leukaemia. The aim is to understand the biology of the disease and use this knowledge to develop economically viable therapies. As Sujjawal Ahmad joins the team on this project having inspired from the scope and vision of the Centre, he conveys his admiration.

The Aga Khan University –University of Ca​​lifornia, San Francisco (UCSF) partnership began a comprehensive and integrated research programme at AKU in stem cell biology and regenerative medicine. Since then, the Centre, under the leadership of Professor Dr El-Nasir M A Lalani , is creating a strong regenerative medicine and stem cell research community across AKU campuses by inducting and training a cadre of clinical researchers, preparing them to undertake ambitious research programmes under the highest ethical, scientific, and medical standards for alleviating disease and improving human health in a state-of-the-art research facility.

Learn more about CRM:

Follow on Linkedin:

Author: Sujjawal Ahmad

The author is a Pakistan-based writer, contact him via email:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.